Trial Profile
Emergency Use of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jun 2021
Price :
$35
*
At a glance
- Drugs Ornithine phenylacetate (Primary)
- Indications Liver failure
- Focus Adverse reactions; Expanded access
- Sponsors Ocera Therapeutics
- 28 Nov 2014 New trial record